Emerald Advisers LLC Purchases 57,035 Shares of LivaNova PLC (NASDAQ:LIVN)

Emerald Advisers LLC increased its position in LivaNova PLC (NASDAQ:LIVN) by 8.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 752,540 shares of the company’s stock after acquiring an additional 57,035 shares during the quarter. LivaNova comprises about 1.4% of Emerald Advisers LLC’s holdings, making the stock its 18th biggest holding. Emerald Advisers LLC’s holdings in LivaNova were worth $34,850,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Central Pacific Bank Trust Division boosted its position in shares of LivaNova by 21.2% in the fourth quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock valued at $191,000 after acquiring an additional 720 shares during the period. Captrust Financial Advisors bought a new stake in LivaNova during the third quarter valued at approximately $217,000. Sanctuary Advisors LLC bought a new stake in LivaNova during the third quarter valued at approximately $219,000. Vestcor Inc bought a new stake in LivaNova during the fourth quarter valued at approximately $204,000. Finally, Edgestream Partners L.P. bought a new stake in LivaNova during the third quarter valued at approximately $244,000. 97.64% of the stock is currently owned by institutional investors.

LivaNova Stock Down 2.3 %

Shares of NASDAQ LIVN opened at $39.48 on Friday. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. LivaNova PLC has a 52 week low of $36.85 and a 52 week high of $64.48. The firm’s fifty day moving average is $45.31 and its 200 day moving average is $48.74. The company has a market cap of $2.15 billion, a price-to-earnings ratio of 94.00 and a beta of 1.10.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Stifel Nicolaus dropped their target price on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, February 26th. Needham & Company LLC reiterated a “buy” rating and set a $64.00 target price on shares of LivaNova in a research report on Monday, March 17th. Wolfe Research lowered shares of LivaNova from an “outperform” rating to a “peer perform” rating in a research report on Wednesday, February 26th. The Goldman Sachs Group decreased their price target on shares of LivaNova from $64.00 to $55.00 and set a “buy” rating on the stock in a research note on Monday, March 3rd. Finally, Mizuho decreased their price target on shares of LivaNova from $70.00 to $60.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, LivaNova currently has an average rating of “Moderate Buy” and a consensus target price of $61.17.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.